NY-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer.
NY-CO-58/KIF2C has been identified as a tumor antigen by screening antibody responses in patients with colorectal cancer. However, expression had not consequently been examined, and nothing was known about its ability to induce spontaneous T cell responses, which have been suggested to play a role i...
Main Authors: | Gnjatic, S, Cao, Y, Reichelt, U, Yekebas, E, Nölker, C, Marx, A, Erbersdobler, A, Nishikawa, H, Hildebrandt, Y, Bartels, K, Horn, C, Stahl, T, Gout, I, Filonenko, V, Ling, K, Cerundolo, V, Luetkens, T, Ritter, G, Friedrichs, K, Leuwer, R, Hegewisch-Becker, S, Izbicki, JR, Bokemeyer, C, Old, L, Atanackovic, D |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2010
|
Similar Items
-
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
by: Chen, J, et al.
Published: (2015) -
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.
by: Chen, J, et al.
Published: (2000) -
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele.
by: Gnjatic, S, et al.
Published: (2000) -
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.
by: Jäger, E, et al.
Published: (2000) -
Failure of a Multi-Centric Clinical Trial Investigating Neoadjuvant Radio-Chemotherapy in Resectable Pancreatic Carcinoma (NEOPA-NCT01900327)—Which Lessons Are Learnt?
by: Michael Tachezy, et al.
Published: (2023-08-01)